Abbott (ABT) and the Drugs for Neglected Diseases initiative or DNDi reached a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world's most neglected tropical diseases, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness. Through this collaboration, DNDi and Abbott scientists would focus initial efforts on discovering and advancing novel antimicrobial agents with activity against these neglected diseases.
Abbott said this new deal expands this relationship, and provides DNDi access to selected classes of molecules and accompanying data generated by Abbott that are crucial for the development of effective and accessible new treatments for neglected diseases.
The deal implies both DNDi and Abbott share their unique scientific expertise and resources, DNDi gains access to Abbott compounds, data and information to accelerate drug development, non-exclusive licensing structure for relevant IP in the neglected diseases field provides flexibility and any resulting products would be provided in endemic countries at the lowest sustainable price to expand patient access.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.